PCSK9 Inhibitor Evolocumab Significantly Reduces Adverse Cardiovascular Events When Added to Statin Therapy With No Major Safety Concerns

In patients with cardiovascular disease, evolocumab reduced LDL cholesterol by 59 percent and reduced the risk of adverse cardiovascular outcomes with greater benefit the longer the duration of therapy.
Source: BWH News - Category: Hospital Management Source Type: news